- Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years
-
Seontae Kim, Yeseul Heo, Soon-Young Seo, Do Sang Lim, Enhi Cho, Yeon-Kyeng Lee
-
Osong Public Health Res Perspect. 2022;13(5):382-390. Published online October 14, 2022
-
DOI: https://doi.org/10.24171/j.phrp.2022.0233
-
-
3,655
View
-
129
Download
-
4
Web of Science
-
6
Crossref
-
Abstract
PDF
- Objectives
This study aimed to identify potential safety signals and adverse events following the primary Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccination series among children and adolescents aged 5 to 17 years in the Republic of Korea. Methods: Adverse events reported through the COVID-19 vaccination management system (CVMS, a web-based passive vaccine safety surveillance system) and adverse events and health conditions collected from a text message-based survey were analyzed. Results: A total of 14,786 adverse events among 5 to 17-year-old children and adolescents were reported in the CVMS; 14,334 (96.9%) were non-serious and 452 (3.1%) were serious, including 125 suspected cases of acute cardiovascular injury and 101 suspected cases of anaphylaxis. The overall reporting rate was lower in 5 to 11-year-old children (64.5 per 100,000 doses) than in 12 to 17-year-old adolescents (300.5 per 100,000 doses). The text message survey identified that local and systemic adverse events after either dose were reported less frequently in 5 to 11-year-old children than in 12 to 17-year-old adolescents (p<0.001). The most commonly reported adverse events were pain at the injection site, myalgia, headache, and fatigue/tiredness. Conclusion: The overall results are consistent with the results of controlled trials; serious adverse events were extremely rare among 5 to 17-year-old children and adolescents following Pfizer-BioNTech COVID-19 vaccination. Adverse events were less frequent in children aged 5 to 11 years than in adolescents aged 12 to 17 years.
-
Citations
Citations to this article as recorded by 
- The descriptive epidemiology of adverse events following two doses of mRNA COVID-19 vaccination in Curaçao, the Caribbean
Jonathan Lambo, Sirving Keli, Shaheen Khan Kaplan, Temiloluwa Njideaka-Kevin, Sireesha Bala Arja, Alaa Khedir Omer Altahir, Itunu Olonade, Rohit Kumar Infectious Diseases.2025; 57(2): 137. CrossRef - Myocarditis and Pericarditis are Temporally Associated with BNT162b2 COVID-19 Vaccine in Adolescents: A Systematic Review and Meta-analysis
Yongyeon Choi, Jue Seong Lee, Young June Choe, Hyeran Lee, Yoonsun Yoon, Seung Hwan Shin, Myung-Jae Hwang, HyoSug Choi, Sara Na, Jong Hee Kim, Hyun Mi Kang, Bin Ahn, Kyoungsan Seo, Sangshin Park Pediatric Cardiology.2024;[Epub] CrossRef - mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study
Phyumar Soe, Otto G. Vanderkooi, Manish Sadarangani, Monika Naus, Matthew P. Muller, James D. Kellner, Karina A. Top, Hubert Wong, Jennifer E. Isenor, Kimberly Marty, Hennady P. Shulha, Gaston De Serres, Louis Valiquette, Allison McGeer, Julie A. Bettinge The Lancet Regional Health - Americas.2024; 40: 100949. CrossRef - Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea
Seok-Kyoung Choi, Seontae Kim, Mijeong Ko, Yeseul Heo, Tae Eun Kim, Yeonkyeong Lee, Juyeon Jang, Eunok Bahng Osong Public Health and Research Perspectives.2024; 15(6): 542. CrossRef - Safety monitoring of COVID-19 vaccines: February 26, 2021, To June 4, 2022, Republic of Korea
Yeon-Kyeng Lee, Yunhyung Kwon, Yesul Heo, Eun Kyoung Kim, Seung Yun Kim, Hoon Cho, Seontae Kim, Mijeong Ko, Dosang Lim, Soon-Young Seo, Enhi Cho Clinical and Experimental Pediatrics.2023; 66(10): 415. CrossRef - Effectiveness of the BNT162b2 vaccine in preventing morbidity and mortality associated with COVID-19 in children aged 5 to 11 years: A systematic review and meta-analysis
Sumayyah Ebrahim, Ntombifuthi Blose, Natasha Gloeck, Ameer Hohlfeld, Yusentha Balakrishna, Rudzani Muloiwa, Andy Gray, Andy Parrish, Karen Cohen, Ruth Lancaster, Tamara Kredo, Julia Robinson PLOS Global Public Health.2023; 3(12): e0002676. CrossRef
- Presumed population immunity to SARS-CoV-2 in South Korea, April 2022
-
Eun Jung Jang, Young June Choe, Seung Ah Choe, Yoo-Yeon Kim, Ryu Kyung Kim, Jia Kim, Do Sang Lim, Ju Hee Lee, Seonju Yi, Sangwon Lee, Young-Joon Park
-
Osong Public Health Res Perspect. 2022;13(5):377-381. Published online October 14, 2022
-
DOI: https://doi.org/10.24171/j.phrp.2022.0209
-
-
3,616
View
-
80
Download
-
3
Web of Science
-
4
Crossref
-
Graphical Abstract
Abstract
PDF

- Objectives
We estimated the overall and age-specific percentages of the Korean population
with presumed immunity against severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) as of April 2022 using the national registry.
Methods We used the national coronavirus disease 2019 (COVID-19) infection and vaccination
registry from South Korea, as described to define individuals with a previous history of
COVID-19 infection, vaccination, or both, as persons with presumed immunity.
Results Of a total of 53,304,627 observed persons, 24.4% had vaccination and infection, 58.1%
had vaccination and no infection, 7.6% had infection and no vaccination, and 9.9% had no
immunity. The SARS-CoV-2 Omicron variant emerged at a time when the presumed population
immunity ranged from 80% to 85%; however, nearly half of the children were presumed to
have no immunity.
Conclusion We report a gap in population immunity, with lower presumed protection in
children than in adults. The approach presented in this work can provide valuable informed
tools to assist vaccine policy-making at a national level.
-
Citations
Citations to this article as recorded by 
- Realistic Estimation of COVID-19 Infection by Seroprevalence Surveillance of SARS-CoV-2 Antibodies: An Experience From Korea Metropolitan Area From January to May 2022
In Hwa Jeong, Jong-Hun Kim, Min-Jung Kwon, Jayoung Kim, Hee Jin Huh, Byoungguk Kim, Junewoo Lee, Jeong-hyun Nam, Eun-Suk Kang Journal of Korean Medical Science.2024;[Epub] CrossRef - Epidemiology of Coronavirus Disease 2019 in Infants and Toddlers, Seoul, South Korea
JiWoo Sim, Euncheol Son, Young June Choe Pediatric Infection & Vaccine.2024; 31(1): 94. CrossRef - Predicting adherence to COVID-19 preventive measures among South Korean adults aged 40 to 69 Years using the expanded health empowerment model
Su-Jung Nam, Tae-Young Pak SSM - Population Health.2023; 22: 101411. CrossRef - Acute COVID-19 in unvaccinated children without a history of previous infection during the delta and omicron periods
Jee Min Kim, Ji Yoon Han, Seung Beom Han Postgraduate Medicine.2023; 135(7): 727. CrossRef
|